Autoimmune Aspects of Vitiligo

References

• Tosti A., Bardazzi E., Tosti G., Monti L. Audi-tologic abnormalities in cases of vitiligo. J. Am. Acad. Dermatol 1987; 17: 230–233
   PubMed Web of Science ®Google Scholar
• Lerner A. B., Nordlund J. J., Albert D. M. Pigment cells of the eyes in people with vitiligo. New Eng. J. Med. 1977; 296: 232
   PubMedGoogle Scholar
• Howitz J., Brodthagen H., Schwartz M., Tomsen K. Prevalence of vitiligo: epidemiological survey on the Isle of Bornholm, Denmark. Arch. Dermatol 1977; 113: 47–52
   PubMedGoogle Scholar
• Mehta N., Shah K., Theodore C., Vyas V., Patel A. Epidemiologic study of vitiligo in Surat area, South Gujarat. Indian J. Med. Res. 1973; 61: 145–154
   PubMed Web of Science ®Google Scholar
• Majumder P. P., Nordlund J. J., Nath S. K. Pattern of familial aggregation of vitiligo. Arch. Dermatol 1993; 129: 994–998
   PubMedGoogle Scholar
• Ortonne J. P., Mosher D. B., Fitzpatrick T. B. Vitiligo and other hypomelanoses of hair and skin. Topics in Dermatology, J P Ortonne, D. B. Mosher, T B Fitzpatrick. Plenum Medical Book Co., New York 1983; 257–258
   Google Scholar
• Porter J. R., Beuf A. H., Lerner A., Norland J. J. Psychosocial effect of vitiligo: a comparison of vitiligo patients with normal control subjects, with psoriasis patients, and with patients with other pigmentary disorders. J. Am. Acad. Dermatol 1986; 15: 220–224
   PubMed Web of Science ®Google Scholar
• Kent G., Abadie A T M.S.K. Psychologic effects of vitiligo: a critical incident analysis. J. Am. Acad. Dermatol 1996; 35: 895–898
   PubMed Web of Science ®Google Scholar
• Pawelek J., Korner A., Bergstrom A. New regulation of melanin biosynthesis and autodestruction of melanoma cells. Nature 1980; 286: 617–619
   PubMed Web of Science ®Google Scholar
• Moellmann G., Klein-Angerer S., Scollay D. A., Nordlund J. J., Lerner A. B. Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. J. Invest. Dermatol 1982; 79: 321–330
   PubMed Web of Science ®Google Scholar
• Nordlund J. J., Lerner A. B. Vitiligo. It is important. Arch. Dermatol 1982; 118: 5–8
   PubMedGoogle Scholar
• Schallreuter K. U., Wood J. M., Berger J. Low catalase levels in the epidermis of patients with vitiligo. J. Invest. Dermatol 1991; 97: 1081–1085
   PubMed Web of Science ®Google Scholar
• Schallreuter K. U., Wood J. M., Ziegler I., Lemke K. R., Pit-Tlekow M. R., Lindsay N. J., Gutlich M. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochim. Biophys. Acta 1994; 1226: 181–192
   PubMed Web of Science ®Google Scholar
• Al'Abadie M. S. K., Warren M. A., Bleehan S. S., Gawkrodger D. J. Morphologic observations on the dermal nerves in vitiligo: an ultrastructural study. Int. J. Dermatol 1995; 34: 837–840
   PubMed Web of Science ®Google Scholar
• Al'Abadie M. S. K., Senior H. J., Bleehan S. S., Gawkrodger D. J. Neuropeptide and neuronal marker studies in vitiligo. Br. J. Dermatol 1994; 131: 160–165
   PubMed Web of Science ®Google Scholar
• Lerner A. Vitiligo. J. Invest. Dermatol 1959; 32: 285–310
   PubMed Web of Science ®Google Scholar
• Ochi Y., De Groot L. J. Vitiligo in Graves' disease. Ann. Intern. Med. 1969; 71: 935–940
   PubMed Web of Science ®Google Scholar
• Macaron C., Winter R. J., Traisman H. S., Kahan B. D., Lasser A. E., Green O. C. Vitiligo and juvenile diabetes mellitus. Arch. Dermatol 1977; 113: 1515–1517
   PubMedGoogle Scholar
• Naughton G. K., Eisinger M., Bystryn J. C. Antibodies to normal human melanocytes in vitiligo. J. Exp. Med. 1983; 158: 246–251
   PubMed Web of Science ®Google Scholar
• Bystryn J. C., Naughton G. K. The significance of vitiligo antibodies. J. Dermatol 1985; 12: 1–9
   PubMedGoogle Scholar
• LePoole I. C., Das P. K., van den Wijngaard R. M.J.G.J., Bos J. D., Westerhof W. Review of the etio-pathomechanism of vitiligo: A convergence theory. Exp. Dermatol 1993; 2: 145–153
   PubMedGoogle Scholar
• Boissy R. E., Nordlund J. J. Vitiligo. Cutaneous Medicine and Surgery, K A Arndt, P E LeBoit, J K Robinson, B U Wintroub. W.B. Saunders Co., Philadelphia 1995; 1210–1218
   Google Scholar
• Rose N. R., Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol. Today 1993; 14: 426–429
   PubMedGoogle Scholar
• Albert D. M, Wagoner M. D., Pruett R. C., Nordlund J. J., Lerner A. B. Vitiligo and disorders of the retinal pigment epithelium. Br. J. Ophthalmol 1983; 67: 153–156
   PubMed Web of Science ®Google Scholar
• Wagoner M. D., Albert D. M., Lerner A. B., Kirkwood J., Forget B. M., Nordlund J. J. New observations on vitiligo and ocular disease. Am. J. Ophthalmol 1983; 96: 16–26
   PubMed Web of Science ®Google Scholar
• Cowan C. L., Haider R. M., Grimes P. E., Chakrabarty S. G., Kenney J. A. Ocular disturbances in vitiligo. J. Am. Acad. Dermatol 1986; 15: 17–24
   PubMed Web of Science ®Google Scholar
• Hilding D., Ginzberg R. Pigmentation of the stria vascularis. Acta Otolaryngol 1977; 84: 24–37
   PubMed Web of Science ®Google Scholar
• Thurmon T. F., Jackson J., Fowler C. G. Deafness and vitiligo. Birth Defects 1976; 12: 315–320
   PubMedGoogle Scholar
• Sharma V. K., Dawn G., Kumar B. Profile of alopecia areata in Northern India. Int. J. Dermatol 1996; 35: 22–27
   PubMed Web of Science ®Google Scholar
• Dawber R.P.R. Integumentary associations of pernicious anaemia. Br. J. Dermatol 1969; 82: 221–222
   Web of Science ®Google Scholar
• Dunlop D. Eighty-six cases of Addison's disease. Br. Med. J. 1963; 2: 887–891
   PubMedGoogle Scholar
• Neufeld M., Maclaren N. K., Blizzard R. M. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine 1981; 60: 355–362
   PubMed Web of Science ®Google Scholar
• Ahonen P., Myllarniemi S., Sipila M. I., Perheentupa J. Clinical variation of autoimmune polyendocrinopa-thy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. NewEng. J. Med. 1990; 322: 1829–1836
   PubMed Web of Science ®Google Scholar
• Cunliffe W. J., Hall R., Newell D. J., Stevenson C. J. Vitiligo, thyroid disease and autoimmunity. Br. J. Dermatol 1968; 80: 137–139
   Web of Science ®Google Scholar
• Turnbridge W. M. G., Evered D. C., Hall R., Appleton D., Brewis M., Clark E., Grimley-Evans J., Young E., Bird T., Smith P. A. The spectrum of thyroid disease in the community: the Wickham survey. Clin. Endocrinol 1977; 7: 481–492
   PubMed Web of Science ®Google Scholar
• Zauli D., Tosti A., Biasco G., Miserocchi F., Patrizi A., Azzaroni D., Andriani G., Difebo G., Callegari C. Prevalence of autoimmune atrophic gastritis in vitiligo. Digestion 1986; 34: 169–172
   PubMed Web of Science ®Google Scholar
• Mandry R. C., Ortiz L. J., Lugo-Somolinos A., Sanchez J. L. Organ-specific autoantibodies in vitiligo patients and their relatives. Int. J. Dermatol 1996; 35: 18–21
   PubMed Web of Science ®Google Scholar
• Brostoff J., Bor S., Feiwel M. Autoantibodies in patients with vitiligo. Lancet 1969; 2: 177–178
   PubMed Web of Science ®Google Scholar
• Betterle C., Del Prete G. F., Peserico A., Bersani G., Carac-Ciolo F., Trisotto. Autoanibodies in vitiligo. Arch. Dermatol 1976; 112: 1328
   PubMedGoogle Scholar
• Boissy R. E., Lamoreux M. L. Animal models of an acquired pigmentary disorder: vitiligo. Advances in Pigment Cell Research, J Bagnara. Alan R. Liss, Inc., New York 1988; 207–218
   Google Scholar
• Smyth J. R. The Smyth chicken: a model for autoimmune amelanosis. CRC Crit. Rev. Poultry Biol 1989; 2: 1–19
   Google Scholar
• Boissy R. E., Lamont S. J., Smyth J. R. Persistence of abnormal melanocytes in immunosuppressed chickens of the autoimmune “DAM” line. Cell Tissue Res 1984; 235: 663–668
   PubMed Web of Science ®Google Scholar
• Lamont S. J., Smyth J. R. Effect of bursectomy on development of a spontaneous postnatal amelanosis. Clin. Immunol. ImmunopathoL 1981; 21: 407–411
   PubMedGoogle Scholar
• Boyle M. L., Pardue S. L., Smyth J. R. Effect of corticosterone on the incidence of amelanosis in Smyth delayed amelanotic line chickens. Poultry Scl 1987; 66: 363–367
   PubMed Web of Science ®Google Scholar
• Pardue S. L., Fite K. V., Bengston L., Lamont S. J., Boyle S. J., Boyle M. L., Smyth J. R. Enhanced integu-mental and ocular amelanosis following the termination of cyclosporin administration. J. Invest. Dermatol 1988; 88: 758–761
   Web of Science ®Google Scholar
• Erf G. F., Trejo-Skalli A. V., Smyth J. R. T cells in regenerating feathers of Smyth line chickens in vitiligo. Clin. Immunol. ImmunopathoL 1995; 76: 120–126
   PubMedGoogle Scholar
• Erf G. F., Smyth J. R. Alterations in blood leukocyte populations in Smyth line chickens with autoimmune vitiligo. Poultry Scl 1996; 75: 351–356
   PubMed Web of Science ®Google Scholar
• Austin L. M., Boissy R. E., Jacobsen B. S., Smyth J. R. The detection of melanocyte autoantibodies in the Smyth chicken model for vitiligo. Clin. Immunol. ImmunopathoL 1992; 64: 112–120
   PubMedGoogle Scholar
• Searle E. A., Boissy R. E., Austin L. M., Nordlund J. J. Smyth chicken melanocyte autoantibodies: cross-reactivity, in vivo binding, and plasma membrane location of the antigen(s). J. Invest. Dermatol 1991; 96: 631
   Web of Science ®Google Scholar
• Austin L. M., Boissy R. E. Mammalian tyrosi-nase-related protein-1 is recognised by autoantibodies from vitiliginous Smyth chickens. Am. J. Pathol 1995; 146: 1529–1541
   PubMed Web of Science ®Google Scholar
• Naughton G. K., Mahaffey M., Bystryn J. C. Antibodies to surface antigens of pigmented cells in animals with vitiligo. Proc. Soc. Exp. Biol. Med. 1986; 181: 423–426
   PubMed Web of Science ®Google Scholar
• Parrish J. A., Fitzpatrick T. B., Shea C., Pathak M. Photochemotherapy of vitiligo: Use of orally administered psoralens and a high intensity longwave ultraviolet light system. Arch. Dermatol 1976; 112: 1531–1534
   PubMed Web of Science ®Google Scholar
• Kumari J. Vitiligo treated with topical clobetasol propionate. Arch. Dermatol 1984; 120: 631–635
   PubMedGoogle Scholar
• Tsuji T., Hamada T. Topically administered fluorouracil in vitiligo. Arch. Dermatol 1983; 119: 722–777
   PubMed Web of Science ®Google Scholar
• Maclaren N. K., Riley W. J. Inherited susceptibility to autoimmune Addison's disease is linked to human leukocyte antigens -DR3 and/or -DR4, except when associated with type I autoimmune polyglandular syndrome. J. Clin. Endocrinol. Metab 1986; 62: 455–459
   PubMed Web of Science ®Google Scholar
• Dahlberg P. A., Holmlund G., Karlsson F. A., Safwen-Berg J. HLA-A, -B, -C and -DR antigens in patients with Graves' disease and their correlation with signs and clinical course. Acta Endocrinologica 1981; 97: 42–47
   PubMedGoogle Scholar
• Platz P., Jakobsen B. K., Morling N., Ryder L. P., Svej-gaardThomsen A. M., Christy M., Kromann H., Benn H., Nerup J., Green A., Hauge M. HLA-D and DR antigens in genetic analysis of insulin-dependent diabetes mellitus. Diabetologica 1981; 21: 108–115
   PubMed Web of Science ®Google Scholar
• Buc M., Busova B., Hegyi E., Kolibasova K. Vitiligo is associated with HLA-A2 and HLA-Dw7 in the Slovak population. Folia Biol 1996; 42: 23–25
   PubMed Web of Science ®Google Scholar
• Finco O., Cuccia M., Martineti M., Ruberto G., Orecchia G., Rabbiosi G. Age onset in vitiligo: relationship with HLA seratypes. Clin. Genetics 1991; 39: 48–54
   PubMed Web of Science ®Google Scholar
• Venneker G. T., Westerhof W., de Vries I. J., Drayer N. M., Wolthers B. G., de Waal L. P., Bos J. D., Asghar S. S. Molecular heterogeneity of the fourth component of complement (C4) and its genes in vitiligo. J. Invest. Dermatol 1992; 99: 853–858
   PubMed Web of Science ®Google Scholar
• Al-Fouzan A., Al-Arbash M., Fouad F., Kaaba S. A., Mousa M. A., Al-Harbi S. A. Study of HLA class I/II and T lymphocyte subsets in Kuwaiti vitiligo patients. Eur. J. Immunogenet 1995; 22: 209–213
   PubMedGoogle Scholar
• Venkataram M. N., White A. G., Leeny W. A., Suwaid A. R.A.L., Daar A. S. HLA antigens in Omani patients with vitiligo. Clin. Exp. Dermatol 1995; 20: 35–37
   PubMed Web of Science ®Google Scholar
• Poloy A., Tibor L., Kramer J., Anh-Tuan N., Kraszits E., Medgyessy I., Fust G., Stensky V., Farid N. R. HLA-DR1 is associated with vitiligo. Immunol. Letters 1991; 27: 59–62
   PubMed Web of Science ®Google Scholar
• Dunston G., Haider R. Vitiligo is associated with HLA-DR4 in black patients: a preliminary report. Arch. Dermatol 1990; 126: 56–60
   PubMedGoogle Scholar
• Foley L. M., Lowe N. J., Misheloff E., Tiwari J. L. Assocaition of HLA-DR4 with vitiligo. J. Am. Acad. Dermatol 1983; 38: 39, 40
   Google Scholar
• Lorini R., Orecchia G., Martinetti M., Dugoujon J. M., Cuccia M. Autoimmunity in vitiligo: relationship with HLA, Gm, and Km polymorphisms. Autoimmunity 1992; 11: 255–260
   PubMed Web of Science ®Google Scholar
• Metzker A., Zamir R., Gazit E., David M., Feuerman E. J. Vitiligo and HLA system. Dermatologica 1980; 160: 100–105
   PubMedGoogle Scholar
• Orecchia G., Perfetti P., Malagoli P., Borghini F., Kipervarg Y. Vitiligo is associated with a significant increase in HLA-A30, Cw6, and DQw3 and a decrease in C4Q0 in northern Italian patients. Dermatology 1992; 185: 123–127
   PubMed Web of Science ®Google Scholar
• Schallreuter K. U., Levenig C., Kiihnl P., Loliger C., Hohl-Tehari M., Berger J. Histocompatability antigens in vitiligo: Hamburg study on 102 patients from northern Germany. Dermatology 1993; 187: 186–192
   PubMed Web of Science ®Google Scholar
• Brunet J. F., Denizot K., Luciani M. F., Roux-Dosseto M., Suzan M., Mattei M. G., Golstein P. A new member of the immunoglobulin superfamily - CTLA-4. Nature 1987; 328: 267–270
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Freeman G. J., Boussiotis V. A., Rennert P., Jellis C. L., Greenfield E., Barber M., Restivo V. A., Ke X. Y., Gray G. S., Nadler L. M. CTLA-4 mediates antigen-specific apoptosis of human T cells. Proc. Natl. Acad. Sci. (USA) 1995; 92: 811–815
   PubMed Web of Science ®Google Scholar
• Walunas T. L., Lenschow D. J., Bakker C. Y., Linsley P. S., Freeman G. J., Green J. M., Thompson C. B., Bluestone J. A. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405–413
   PubMed Web of Science ®Google Scholar
• Kotsa K., Watson P. F., Weetman A. P. A CTLA-4 gene polymorphism is associated with both Graves' disease and autoimmune hypothyroidism. Clin. Endocrinol 1997; 46: 551–554
   PubMed Web of Science ®Google Scholar
• Kemp E. H., Ajjan R. A., Husebye E. S., Peterson P., Uibo R., Imrie H., Pearce S. H. S., Watson P. F., Weetman A. P. A cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism is associated with autoimmune Addison's disease in English patients. Clin. Endocrinol 1998; 49: 609–613
   PubMed Web of Science ®Google Scholar
• Polymeropoulos M. H., Xiao H., Rath D. S., Merril C. R. Dinucleotide repeat polymorphism at the human CTLA-4 gene. Nucleic Acids Res 1991; 19: 4018
   Google Scholar
• Kemp E. H., Ajjan R. A., Waterman E. A., Gawkrodger D. J., Cork M. J., Watson P. F., Weetman A. P. Analysis of a microsatellite polymorphism of the cytotoxic T lymphocyte antigen-4 gene in patients with vitiligo. Br. J. Dermatol 1999; 140: 73–78
   PubMed Web of Science ®Google Scholar
• Stites D. P. Clinical laboratory methods for detection of cellular immunity. Basic and Clinical Immunology, 8th edition, D. P Stites, A I Terr, T G Parslow. Appleton and Lange, Nor-walk (CT) 1994; 199
   Google Scholar
• Soubiran P., Benzaken S., Bellet C., Lacour J. P., Ortonne J. P. Vitiligo: peripheral T-cell subset imbalance as defined by monoclonal antibodies. Br. J. Dermatol 1985; 113: 124
   PubMed Web of Science ®Google Scholar
• D'Amelio R., Frati C., Fattorossi A., Aiuti F. Peripheral T-cell subset imbalance in patients with vitiligo and in their apparently healthy first-degree relatives. Ann. Allergy 1990; 65: 143–145
   PubMedGoogle Scholar
• Abdel-Naser M. B., Ludwig W. D., Gollnick H., Orfanos C. E. Non-segmental vitiligo: Decrease of the CD45RA+ T-cell and evidence of peripheral T-cell activation. Int. J. Dermatol 1992; 31: 321–326
   PubMed Web of Science ®Google Scholar
• Grimes P. E., Ghoneum M., Stockton X., Payne C., Kelly A. P., Alfred L. T-cell profiles in vitiligo. J. Am. Acad. Dermatol 1986; 14: 196–201
   PubMed Web of Science ®Google Scholar
• Haider R. M., Walters C. S., Johnson B. A., Chakarabarti S. G., Kenney J. A. Aberrations in T lymphocytes and natural killer cells in vitiligo: a flow cytometric study. J. Am. Acad. Dermatol 1986; 14: 733–737
   PubMed Web of Science ®Google Scholar
• Ogg G. S., Dunbar P. R., Romero P., Chen J. L., Cerund-Olo V. High frequency of skin-homing melano-cyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J. Exp. Med. 1998; 188: 1203–1208
   PubMed Web of Science ®Google Scholar
• Al Badri A. M. T., Todd P. M., Garioch J. J., Gudgeon J. E., Stewart D. G., Goudie R. B. An immunohistolog-ical study of cutaneous lymphocytes in vitiligo. J. Pathol 1994; 170: 149–155
   Web of Science ®Google Scholar
• Abdel-Naser M. B., Kriiger-Krasagakes S., Krugerakis K., Gollnick H., Orfanos C. E. Further evidence for involvement of both cell mediated and humoral immunity in generalised vitiligo. Pigment Cell Res 1994; 7: 1–8
   PubMedGoogle Scholar
• LePoole I. C., van den Wijngaard R. M.J.G.J., Westerhof W., Das P. K. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am. J. Pathol 1996; 148: 1219–1228
   PubMed Web of Science ®Google Scholar
• Tu C. X., Fu H. W., Lin X. R. Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo. J. Dermatological Sci. 1999; 21: 59–62
   PubMed Web of Science ®Google Scholar
• Yeo U. C., Yang Y. S., Park K. B., Sung H. T., Jung S. Y., Lee E. S., Shin M. H. Serum concentration of the soluble interleukin-2 receptor in vitiligo patients. J. Dermatological Sci. 1999; 19: 182–188
   PubMed Web of Science ®Google Scholar
• Yu H. S., Chang K. L., Yu C. L., Li H. F., Wu M. T., Wu C. S., Wu C. S. Alterations in IL-6, IL-8, GM-CSF, TNF-a, and IFN-y release by peripheral mononuclear cells in patients with active vitiligo. J. Invest. Dermatol 1997; 108: 527–529
   PubMed Web of Science ®Google Scholar
• Kirnbauer R., Charvat B., Schauer K., Kock A., Urbanshi A., Forster E., Neuner P., Assmann I., Luger T. A., Schwarz T. Modulation of intercellular adhesion molecule-1 expression on human melanocytes and melanoma cells: evidence for a regulatory role of IL-6, IL-7, TNF-a and UVB light. J. Invest. Dermatol 1992; 98: 320–326
   PubMed Web of Science ®Google Scholar
• Imokawa G., Yada Y., Kimura M., Morisaki N. Granulocyte/macrophage colony-stimulating factor is an intrinsic growth factor for human melanocytes in UVA-induced melanosis. Biochem. J. 1996; 313: 625–631
   PubMed Web of Science ®Google Scholar
• Probert L., Plows D., Kontogeorgos G., Kollias G. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-trans-genic mice. Eur. J. Immunol 1995; 25: 1794–1797
   PubMed Web of Science ®Google Scholar
• Claudy A., Rouchouse B. Langerhans cells and vitiligo: quantitative study of T6 and HLR-DR antigen-expressing cells. Acta Dermatol. Venereal 1984; 64: 334–336
   PubMed Web of Science ®Google Scholar
• Riley P. Distribution of epidermal dendritic cells in pigmented and unpigmented skin. J. Invest. Dermatol 1967; 48: 28–38
   PubMed Web of Science ®Google Scholar
• Al Badri A. M. T., Foulis A. K., Todd P. M., Garioch J. J., Gudgeon J. E., Stewart D. G., Gracie J. A., Goudie R. B. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo. J. Pathol 1993; 169: 203–206
   PubMed Web of Science ®Google Scholar
• Le Poole I. C., Mutis C., van den Wrjngaard R. M.J.G.J., Westerhof W., Ottenhoff T., de Vries R. R.P., Das P. K. A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J. Immunol 1993; 151: 7284–7292
   PubMed Web of Science ®Google Scholar
• Campbell I. L., Harrison L. C. Molecular pathology of type I diabetes. Mol. Biol. Med. 1990; 7: 299–309
   PubMedGoogle Scholar
• Zheng R. Q. H., Abney E. R., Grubeck-Loebenstein B., Dayan C., Maini R. N., Feldmann M. Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-3 on human thyroid epithelial cellls in Graves' and Hashimoto's diseases. J. Autoimmunity 1990; 3: 727–736
   PubMed Web of Science ®Google Scholar
• Naughton G. K., Eisenger M., Bystryn J. C. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J. Invest. Dermatol 1983; 81: 540–542
   PubMed Web of Science ®Google Scholar
• Harning R., Cui J., Bystryn J. C. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J. Invest. Dermatol 1991; 97: 1078–1080
   PubMedGoogle Scholar
• Naughton G. K., Reggiardo M. D., Bystryn J. C. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J. Am. Acad. Dermatol 1986; 15: 978–981
   PubMed Web of Science ®Google Scholar
• Cui J., Harning R., Henn M., Bystryn J. C. Identification of pigment cell antigens defined by vitiligo antibodies. J. Invest. Dermatol 1992; 98: 162–1655
   PubMed Web of Science ®Google Scholar
• Cui J., Arita Y., Bystryn J. C. Characterisation of vitiligo antigens. Pigment Cell Res 1995; 8: 53–59
   PubMedGoogle Scholar
• Song Y. H., Connor E., Li Y., Zorovich B., Balducci P., Maclaren N. The role of tyrosinase in autoimmune vitiligo. Lancet 1994; 344: 1049–1052
   PubMed Web of Science ®Google Scholar
• Baharav E., Merimski O., Shoenfeld Y., Zigelman R., Gil-Brund B., Yecheskel G. Tyrosinase as an autoan-tigen in patients with vitiligo. Clin. Exp. Immunol 1996; 105: 84–88
   PubMed Web of Science ®Google Scholar
• Kemp E. H., Gawkrodger D. J., MacNeil S., Watson P F., Weetman A. P. Detection of tyrosinase autoantibodies in vitiligo patients using S-labelled recombinant human tyrosinase in a radioimmunoassay. J. Invest. Dermatol 1997; 109: 69–73
   PubMed Web of Science ®Google Scholar
• Kemp E. H., Waterman E. A., Gawkrodger D. J., Watson P. F., Weetman A. P. Autoantibodies to tyrosi-nase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. Br. J. Dermatol 1998; 139: 798–805
   PubMed Web of Science ®Google Scholar
• Okamoto T., Irie R. F., Fujii S., Huang S. K. S., Nizze A. J., Morton D. L., Hoon D. S.B. Anti-tyrosi-nase-related protein-2 immune response in vitiligo and melanoma patients receiving active-specific immunotherapy. J. Invest. Dermatol 1998; 111: 1034–1039
   PubMed Web of Science ®Google Scholar
• Kemp E. H., Gawkrodger D. J., Watson P. F., Weetman A. P. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Clin. Exp. Immunol 1997; 109: 495–500
   PubMedGoogle Scholar
• Kemp E. H., Gawkrodger D. J., Watson P. F., Weetman A. P. Autoantibodies to human melanocyte-specific protein Pmell7 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA). Clin. Exp. Immunol 1998; 114: 333–338
   PubMed Web of Science ®Google Scholar
• Norris D. A., Kissinger R. M., Naughton G. K., Bystryn J. C. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocyes in vitroby complement-mediated damage and antibody-dependent cellular cytotoxicity. J. Invest. Dermatol 1988; 90: 783–789
   PubMed Web of Science ®Google Scholar
• Gilhar A., Zelickson B., Ulman Y., Etzioni A. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J. Invest. Dermatol 1995; 105: 683–686
   PubMed Web of Science ®Google Scholar
• Norris D. A., Capin L., Muglia J. J., Osborn R. L., ZerbeBystryn G. O.J.-C., Tonnesen M. G. Enhanced susceptibility of melanocytes to different immunologic effector mechanisms in vitro: potential mechanisms for post-inflammatory hypopigmentation and vitiligo. Pigment Cell Res. Suppl 1988; 1: 113–123
   Google Scholar
• Yu J., Kao C., Yu C. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo. J. Invest. Dermatol 1993; 100: 823–828
   PubMed Web of Science ®Google Scholar
• Aronson P., Hashimoto K. Association of IgA antimelanoma antibodies in the sera of vitiligo patients with active disease. J. Invest. Dermatol 1987; 88: 475
   Web of Science ®Google Scholar
• Wojdani A., Grimes P. E., Loeb L. J., Kelly A. P., Gho-Neum M. Detection of antibenzene ring antibodies in patients with vitiligo. J. Invest. Dermatol 1992; 98: 644
   Web of Science ®Google Scholar
• Merimsky O., Shoenfeld Y., Yecheskel G., Chaitchik S., Azizi E., Fishman P. Vitiligo and melanoma associated hypopigmentation: a similar appearance but a different mechanism. Cancer Immunol. Immunother 1994; 38: 411–416
   PubMed Web of Science ®Google Scholar
• Bystryn J. C, Rigel D., Friedman R. J., Kopf A. The prognostic significance of vitiligo in patients with melanoma. Arch. Dermatol 1987; 123: 1053–1055
   PubMed Web of Science ®Google Scholar
• Nordlund J. J., Kirkwood J. M., Forget B. M., Milton G., Albert D. M., Lerner A. B. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J. Am. Acad. Dermatol 1983; 9: 689–696
   PubMed Web of Science ®Google Scholar
• Laucius J. F., Mastrangelo M. J. Cutaneous dep-igmentary phenomena in patients with malignant melanoma. Human malignant melanoma, J F Laucius, M J Mastrangelo. Grune and Stratton, Philadelphia 1979; 209–225
   Google Scholar
• Millikan L. E., Hook R. R., Manning P. J. Gross and ultrastructural changes in a new melanoma model: the Sinclair swine. Yale J. Biol. Med. 1973; 46: 631–645
   PubMed Web of Science ®Google Scholar
• Naughton G. K., Mahaffey M., Bystryn J. C. Antibodies to surface antigens of pigmented cells in animals with vitiligo. Proc. Soc. Exp. Biol. Med. 1986; 181: 423–426
   PubMed Web of Science ®Google Scholar
• Berkelhammer J., Ensign B. M., Hook R. R., Hecker C. J., Smith G. D., Oxenhandler R. W. Growth and spontaneous regression of swine melanoma: Relationship of in v/rroleukocyte reactivity. J. Natl. Cancer I. 1982; 68: 461–468
   PubMed Web of Science ®Google Scholar
• Bystryn J. C. Immune mechanisms in vitiligo. Clinics in Dermatol 1997; 15: 853–861
   PubMed Web of Science ®Google Scholar
• Cui J., Bystryn J. C. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch. Dermatol 1995; 131: 314–318
   PubMedGoogle Scholar
• Huang S. K. S., Okamoto T., Morton D. L., Hoon D. S.B. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients. J. Invest. Dermatol 1998; 111: 662–667
   PubMed Web of Science ®Google Scholar
• Brichard V., Van Pel A., Wolfel T., Wolfel C., De Plaen E., Lethe B., Coulie P., Boon T. The tyrosinase gene codes for an antigen recognised by autologous cytotoxic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 1993; 178: 489–495
   PubMed Web of Science ®Google Scholar
• Wang R. R, Robbins P. P., Kawakami Y., Kang X. Q., Rosenberg S. A. Identification of a gene encoding a melanoma tumor antigen recognised by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. 1995; 181: 799–804
   PubMed Web of Science ®Google Scholar
• Wang R. R, Appella E., Kawakami Y., Kang X., Rosenberg S. A. Identification of TRP-2 as a human tumor antigen recognised by cytotoxic T lymphocytes. J. Exp. Med. 1996; 184: 2207–2216
   PubMed Web of Science ®Google Scholar
• Bakker A., Schreurs M., De Boer A., Kawakami Y., Rosenberg S., Adema G., Figdor C. Melanocyte lineage-specific antigen gplOO is recognised by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 1994; 179: 1005–1009
   PubMed Web of Science ®Google Scholar
• Coulie G. C., Brichard V., Van Pel A., Wolfel T., Schneider J., Traversari C., Mattei S., De Plaen E., Lurquin C., Szikora J. P., Renauld J. C., Boon T. A new gene coding for a differentiation antigen recognised by autologous cytotoxic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 1994; 180: 35–42
   PubMed Web of Science ®Google Scholar
• Merimsky O., Shoenfeld Y., Baharav E., Altomonte M., Chaitchik S., Maio M., Ferrone S., Fishman P. Melanoma-associated hypopigmentation: Where are the antibodies? Am. J. Clin. Oncol 1996; 19: 613–618
   Web of Science ®Google Scholar
• Merimsky O., Baharav E., Shoenfeld Y., Chaitchik S., Tsigelman R., Cohenaloro D., Fishman P. Anti-tyrosinase antibodies in malignant melanoma. Cancer Immunol. Immunother 1996; 42: 297–302
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., White D. E. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunology 1996; 19: 81–84
   PubMed Web of Science ®Google Scholar
• Weber L. W., Browne W. B., Wolchock J. D., Srinivasan R., Qin J., Moroi Y., Clynes R., Song P., Lewis J. J., Houghton A. N. Tumor immunity and autoimmunity induced by immunisation with homologous DNA. J. Clin. Invest 1998; 102: 1258–1264
   PubMed Web of Science ®Google Scholar
• Overwijk W. W., Lee D. S., Surman D. R., Irvine K. R., Tou-Loukian K. R., Chan C. C., Carroll M. W., Moss B., Rosenberg S. A., Restifo N. P. Vaccination with recombinant vaccinia virus encoding a self antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4+ lymphocytes. Proc. Natl. Acad. Sci. (USA) 1999; 96: 2982–2987
   PubMed Web of Science ®Google Scholar
• Bowne W. B., Srinivasan R., Wolchok J. D., Hawkins W. G., Blachere N. E., Dyall R., Lewis J. J., Houghton A. N. Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med. 1999; 190: 1717–1722
   PubMed Web of Science ®Google Scholar
• Xie Z., Chen D. L., Jiao D., Bystryn J. C. Vitiligo antibodies are not directed to tyrosinase. Arch. Dermatol 1999; 135: 417–422
   PubMedGoogle Scholar
• Park Y. K., Kim N. S., Hann S. K., Im S. Identification of autoantibody to melanocytes and characterisation of vitiligo antigen in vitiligo patients. J. Dermatological Sci. 1996; 11: 111–120
   PubMed Web of Science ®Google Scholar